Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.

Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog.

Abstract: A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog.

Abstract: The prime-mover comprises a central inertial barge 1, a first outer wave-engaging pontoon 2 pivotally movable relative to the central barge 1 about the pivotal axis defined by the arrow A, and a second outer wave-engaging pontoon 3 pivotally movable relative to the central barge 1 about the axis defined by the arrow B. Two series of pumps 4 are mounted on the central barge 1 and driven by the pivotal movement of the outer wave-engaging pontoons 2, 3 respectively. A damping mechanism comprising two shafts 6a, 6b extend downwardly from the bage 1. The shafts 6a, 6b are provided with damping plates 7a, 7b at the bottom ends thereof. The damping plates 7a, 7b may be moved relative to the shafts 6a, 6b by being screwed up or down the shafts as required.

Abstract: Leukoregulin is identified, a biologically active lymphokine of molecular weight of about 120,000 to 140,000, with subunits of about 30,000 to 35,000, having the isoelectric focusing pH's of between 4.8 and 5.5 or between 7.5 and 8.3, which has the ability to regulate tumor cell physiology and growth without affecting the growth of normal cells. Methods for stimulating its production by monouclear cells, methods for its isolation and purification, and methods for its therapeutic uses are also disclosed.